Annual Report

Overview

The report describes BioPorto's 2022 execution on its NGAL diagnostic program, including completion of a three-part pediatric clinical study and submission of a US FDA marketing authorization application. Consolidated revenue was DKK 28,969 thousand, with European commercialization continuing. The CSR disclosures state that BioPorto signed the UN Global Compact and set a target for at least 40% underrepresented gender representation on the Board by 2026.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services